Barclays has initiated coverage on Elanco Animal Health Inc (ELAN) with an Overweight rating, marking its first assessment of the company's investment potential. This decision reflects Barclays' analysis of Elanco's business operations, industry dynamics, and growth prospects.
Elanco, headquartered in Greenfield, Indiana, develops, manufactures, and markets products for both pets and farm animals. The company employs approximately 9,000 full-time staff and operates in over 90 countries. Its diverse portfolio includes around 200 brands, targeting various species primarily dogs, cats, cattle, poultry, swine, and sheep. The firm's global pet health offerings focus on parasiticides, vaccines, and therapeutics, featuring products such as Advantage Family, Credelio Family, and Seresto.
As of December 8, 2025, Elanco's stock is priced at $21.39, with a market capitalization of $10.8 billion. The company has reported a trailing twelve-month price-to-earnings ratio of 299.36 and earnings per share of 0.07. Upcoming earnings are scheduled for May 5, 2026, with an estimated EPS of $0.35 and revenue of $1.3 billion.
Analyst ratings serve as a professional perspective based on extensive research, but they reflect assumptions that may not always hold true. Investors are advised to consider various factors, including company fundamentals and industry trends, when making decisions. Analyst opinions can evolve as new information emerges, highlighting the importance of a comprehensive approach to investment analysis.